Le étude montre que la Mélatonine a des effets anti-cancéreux sur le carcinome du poumon non à petites cellules

Le étude dans Oncotarget montre que la Mélatonine a des effets anti-cancéreux sur le carcinome du poumon non à petites cellules. Les carcinomes non à petites cellules sont rassemblés parce que leur pronostic et leur traitement sont semblables. Représentant 85-90 % des cancers du poumon. La Mélatonine a des effets anti-cancéreux sur le carcinome du poumon non à petites cellules.

Melatonin as a potential anticarcinogen for non-small-cell lung cancer.

Oncotarget. 2016 Apr 18;

Authors: Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ, Yan X

Abstract
Non-small-cell lung cancer (NSCLC) is a leading cause of death from cancer worldwide. Melatonin, an idoleamine discovered in the pineal gland, exerts pleiotropic anticancer effects against a variety of cancer types. In particular, melatonin ( mélatonine )may be an important anticancer drug in the treatment of NSCLC. Herein, we review the correlation between the disruption of the melatonin ( mélatonine )rhythm and NSCLC incidence; we also evaluate the evidence related to the effects of melatonin ( mélatonine )in inhibiting lung carcinogenesis. Special focus is placed on the oncostatic effects of melatonin, including anti-proliferation, induction of apoptosis, inhibition of invasion and metastasis, and enhancement of immunomodulation. We suggest the drug synergy of melatonin ( mélatonine )with radio- or chemotherapy for NSCLC could prove to be useful. Taken together, the information complied herein may serve as a comprehensive reference for the anticancer mechanisms of melatonin ( mélatonine )against NSCLC, and may be helpful for the design of future experimental research and for advancing melatonin ( mélatonine )as a therapeutic agent for NSCLC.

PMID: 27102150 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/27102150?dopt=Abstract